BACKGROUND: The durability of bioprosthetic heart valves is limited by structural valve deterioration (SVD) due to long-term calcification. A novel bioprosthetic tissue (RESILIATM) has been developed which, in preclinical studies, has shown reduced calcification. The purpose of this study was to evaluate the intermediate-term clinical outcomes and hemodynamic performance of this tissue. METHODS: A prospective, single-arm, observational trial was conducted in patients who required surgical aortic valve replacement (AVR). Between July 2011 and February 2013, 133 patients were implanted at two sites in Poland. Hemodynamic performance and clinical outcomes were assessed annually through 4 years of follow-up. All safety events were adjudicated by an independent Clinical Events Committee, and echocardiographic data were evaluated by a core laboratory. RESULTS: Patients were 65.3±13.5 years old and 26% were ≤60 years old. The average follow-up was 3.8±1.1 (median: 4.1; IQR, 4.0-4.3) years. Early (≤30 day) and late (>30 day) all-cause mortality rates were 2.3% (n=3) and 3.2% late patient-years (n=16), respectively. There were no cases of early or late SVD. There was one early case of major paravalvular leak (0.8%), and no late cases. At 4 years, the mean gradient was 14.5±7.4 mmHg and the effective orifice area was 1.6±0.4 cm2, both markedly improved from baseline. At 4 years, the New York Heart Association functional class had improved from baseline in 54.5% of patients. CONCLUSIONS: The aortic bioprosthesis with novel RESILIATM tissue demonstrated excellent hemodynamic performance and safety outcomes over 4 years. Longer follow-up will be important to confirm the durability of this bioprosthesis.
BACKGROUND: The durability of bioprosthetic heart valves is limited by structural valve deterioration (SVD) due to long-term calcification. A novel bioprosthetic tissue (RESILIATM) has been developed which, in preclinical studies, has shown reduced calcification. The purpose of this study was to evaluate the intermediate-term clinical outcomes and hemodynamic performance of this tissue. METHODS: A prospective, single-arm, observational trial was conducted in patients who required surgical aortic valve replacement (AVR). Between July 2011 and February 2013, 133 patients were implanted at two sites in Poland. Hemodynamic performance and clinical outcomes were assessed annually through 4 years of follow-up. All safety events were adjudicated by an independent Clinical Events Committee, and echocardiographic data were evaluated by a core laboratory. RESULTS: Patients were 65.3±13.5 years old and 26% were ≤60 years old. The average follow-up was 3.8±1.1 (median: 4.1; IQR, 4.0-4.3) years. Early (≤30 day) and late (>30 day) all-cause mortality rates were 2.3% (n=3) and 3.2% late patient-years (n=16), respectively. There were no cases of early or late SVD. There was one early case of major paravalvular leak (0.8%), and no late cases. At 4 years, the mean gradient was 14.5±7.4 mmHg and the effective orifice area was 1.6±0.4 cm2, both markedly improved from baseline. At 4 years, the New York Heart Association functional class had improved from baseline in 54.5% of patients. CONCLUSIONS: The aortic bioprosthesis with novel RESILIATM tissue demonstrated excellent hemodynamic performance and safety outcomes over 4 years. Longer follow-up will be important to confirm the durability of this bioprosthesis.
Authors: Gary L Grunkemeier; Anthony P Furnary; YingXing Wu; Lian Wang; Albert Starr Journal: J Thorac Cardiovasc Surg Date: 2012-09-23 Impact factor: 5.209
Authors: Yuting P Chiang; Joanna Chikwe; Alan J Moskowitz; Shinobu Itagaki; David H Adams; Natalia N Egorova Journal: JAMA Date: 2014-10-01 Impact factor: 56.272
Authors: YingXing Wu; Eric G Butchart; Jeffrey S Borer; Ajit Yoganathan; Gary L Grunkemeier Journal: Ann Thorac Surg Date: 2014-09-23 Impact factor: 4.330
Authors: Jerzy Sadowski; Krzysztof Bartuś; Bogusław Kapelak; Amy Chung; Maciej Stąpor; Maciej Bochenek Journal: Kardiol Pol Date: 2014-11-05 Impact factor: 3.108
Authors: Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce W Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise Journal: Circulation Date: 2008-09-26 Impact factor: 29.690
Authors: Paolo Stassano; Luigi Di Tommaso; Mario Monaco; Francesco Iorio; Paolo Pepino; Nicola Spampinato; Carlo Vosa Journal: J Am Coll Cardiol Date: 2009-11-10 Impact factor: 24.094
Authors: Alec Vahanian; Ottavio Alfieri; Felicita Andreotti; Manuel J Antunes; Gonzalo Barón-Esquivias; Helmut Baumgartner; Michael Andrew Borger; Thierry P Carrel; Michele De Bonis; Arturo Evangelista; Volkmar Falk; Bernard Lung; Patrizio Lancellotti; Luc Pierard; Susanna Price; Hans-Joachim Schäfers; Gerhard Schuler; Janina Stepinska; Karl Swedberg; Johanna Takkenberg; Ulrich Otto Von Oppell; Stephan Windecker; Jose Luis Zamorano; Marian Zembala Journal: Eur J Cardiothorac Surg Date: 2012-08-25 Impact factor: 4.191
Authors: James M Brown; Sean M O'Brien; Changfu Wu; Jo Ann H Sikora; Bartley P Griffith; James S Gammie Journal: J Thorac Cardiovasc Surg Date: 2009-01 Impact factor: 5.209
Authors: Krzysztof Bartus; Radosław Litwinowicz; Jerzy Sadowski; Grzegorz Filip; Mariusz Kowalewski; Piotr Suwalski; Piotr Mazur; Anna Kędziora; Marek Jasiński; Marek Deja; Mariusz Kuśmierczyk; Pawel Czub; Michal Zembala; Marek Jemielity; Rafał Pawlaczyk; Zdzisław Tobota; Bohdan Maruszewski; Boguslaw Kapelak Journal: J Thorac Dis Date: 2020-10 Impact factor: 3.005
Authors: Karolina Pawelkowska; Stanislaw Bartus; Robert Sobczynski; Michal Medrzycki; Grzegorz Grudzien; Grzegorz Filip; Bartosz Cierpikowski; Krzysztof Bartus; Boguslaw Kapelak Journal: Kardiochir Torakochirurgia Pol Date: 2022-01-09
Authors: Campbell D Flynn; Neil P Curran; Stephanie Chan; Isabel Zegri-Reiriz; Manel Tauron; David H Tian; Gosta B Pettersson; Joseph S Coselli; Martin Misfeld; Manuel J Antunes; Carlos A Mestres; Eduard Quintana Journal: Ann Cardiothorac Surg Date: 2019-11